Sage Therapeutics, Inc. - COM (SAGE)

Historical Portfolio Holders from Q3 2014 to Q3 2024

All holders as of June 30, 2024
Q2 2024
Type / Class
Equity / COM
Shares, excl. options Q2 2024
53.5M
Holdings value Q2 2024
$581M
Value change Q2 2024
-$65.2M
Grand Portfolio weight change Q2 2024
0%
Number of holders
189
Number of buys Q2 2024
106
Number of sells Q2 2024
-89
Average buys Q2 2024 %
+0%
Average sells Q2 2024 %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 14.3K $103K -$14.2K $7.22 2
2024 Q2 53.5M $581M -$65.2M $10.86 190
2024 Q1 58.2M $1.09B +$37.7M $18.74 196
2023 Q4 56.1M $1.22B -$53.6M $21.67 197
2023 Q3 58.4M $1.2B -$19.6M $20.58 192
2023 Q2 54.1M $2.54B +$53.6M $47.02 222
2023 Q1 52.9M $2.22B +$61.1M $41.96 211
2022 Q4 51.6M $1.97B +$219K $38.14 202
2022 Q3 51.4M $2.01B +$16M $39.16 183
2022 Q2 51M $1.65B +$39.7M $32.30 190
2022 Q1 49.9M $1.65B -$26.1M $33.10 191
2021 Q4 50.2M $2.13B +$30.1M $42.54 202
2021 Q3 49M $2.17B -$115M $44.31 218
2021 Q2 50.6M $2.87B -$159M $56.81 250
2021 Q1 53.1M $3.97B -$71.8M $74.85 254
2020 Q4 53.8M $4.65B +$60.5M $86.51 243
2020 Q3 53.6M $3.28B -$18.8M $61.12 223
2020 Q2 54M $2.25B +$2.12M $41.58 207
2020 Q1 55M $1.58B -$222M $28.72 215
2019 Q4 55.9M $4.04B -$417M $72.19 257
2019 Q3 58.2M $8.17B +$23.5M $140.29 275
2019 Q2 58.1M $10.6B +$991M $183.09 268
2019 Q1 56.3M $8.95B +$1.12B $159.05 263
2018 Q4 49.7M $4.76B +$3.5M $95.79 244
2018 Q3 49M $6.92B +$56.8M $141.25 273
2018 Q2 48.6M $7.61B +$162M $156.53 266
2018 Q1 47.5M $7.65B +$645M $161.07 244
2017 Q4 44.1M $7.26B +$681M $164.71 223
2017 Q3 39.3M $2.45B +$48.6M $62.30 168
2017 Q2 38.4M $3.06B +$50.7M $79.64 187
2017 Q1 37.9M $2.69B +$271M $71.07 186
2016 Q4 36.7M $1.88B -$47.8M $51.06 161
2016 Q3 37.8M $1.74B +$399M $46.05 149
2016 Q2 30.2M $911M +$28.4M $30.13 140
2016 Q1 29.1M $932M +$174M $32.06 139
2015 Q4 23.5M $1.37B +$159M $58.30 134
2015 Q3 27.2M $1.15B +$26.7M $42.32 127
2015 Q2 26.4M $1.93B +$372M $73.00 122
2015 Q1 21.5M $1.08B +$82.8M $50.23 91
2014 Q4 19.7M $721M +$20.8M $36.60 70
2014 Q3 18.9M $595M +$595M $31.50 50